Genetic polymorphisms of drug transporters: Pharmacokinetic and pharmacodynamic consequences in pharmacotherapy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 5, 2006, Pages 651-674

  Ieiri, Ichiro ^a   Takane, Hiroshi ^b   Hirota, Takeshi ^a   Otsubo, Kenji ^b   Higuchi, Shun ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Drug transporter; Genetic polymorphism; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER;

DRUG DISTRIBUTION; DRUG TRANSPORT; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PHARMACODYNAMICS; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG THERAPY; HUMANS; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 33846365943     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.5.651     Document Type: Review

References (220)

1. CORDON-CARDO C, O'BRIEN JP, BOCCIA J, CASALS D, BERTINO JR, MELAMED MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. (1990) 38:1277-1287.
2. THIEBAUT F, TSURUO T, HAMADA H, GOTTESMAN MM, PASTAN I, WILLINGHAM MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA (1987) 84:7735-7738.
3. FOJO AT, UEDA K, SLAMON DJ, POPLACK DG, GOTTESMAN MM, PASTAN I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA (1987) 84:265-269.
4. SUGAWARA I, KATAOKA I, MORISHITA Y et al.: Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. (1988) 48:1926-1929.
5. KIM RB, FROMM MF, WANDEL C et al.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. (1998) 101:289-294.
6. MAYER U, WAGENAAR E, BEIJNEN JH et al.: Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br. J. Pharmacol. (1996) 119:1038-1044.
7. NAKAMURA Y, IKEDA S, FURUKAWA T et al.: Function of P-glycoprotein expressed in placenta and mole. Biochem. Biophys. Res. Commun. (1997) 235:849-853.
8. SCHINKEL AH, WAGENAAR E, MOL CA, VAN DEEMTER L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. (1996) 97:2517-2524.
9. CORDON-CARDO C, O'BRIEN JP, CASALS D et al.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA (1989) 86:695-698. 1
10. VAN DE WATER FM, MASEREEUW R, RUSSEL FG: Function and regulation of multidrug resistance proteins (MRPs) in the renal elimination of organic anions. Drug Metab. Rev. (2005) 37:443-471.
11. SUZUKI H, SUGIYAMA Y: Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. (2002) 54:1311-1331. This review describes the basic physiological and pharmacological functions of MRP2 and changes in the functions by genetic variations.
12. BUCHLER M, KONIG J, BROM M et al.: cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. (1996) 271:15091-15098.
13. PAULUSMA CC, BOSMA PJ, ZAMAN GJ et al.: Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (1996) 271:1126-1128.
14. SCHAUB TP, KARTENBECK J, KONIG J et al.: Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J. Am. Soc. Nephrol. (1999) 10:1159-1169.
15. MOTTINO AD, HOFFMAN T, JENNES L, VORE M: Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J. Pharmacol. Exp. Ther. (2000) 293:717-723.
16. CERVENAK J, ANDRIKOVICS H, OZVEGY-LACZKA C et al.: The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology. Cancer Lett. (2006) 234:62-72.
17. MALIEPAARD M, SCHEFFER GL, FANEYTE IF et al.: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. (2001) 61:3458-3464.
18. KRUIJTZER CM, BEIJNEN JH, SCHELLENS JH: Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist (2002) 7:516-530.
19. TAIPALENSUU J, TORNBLOM H, LINDBERG G et al.: Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. (2001) 299:164-170.
20. STAUD F, PAVEK P: Breast cancer resistance protein (BCRP/ABCG2). Int. J. Biochem. Cell Biol. (2005) 37:720-725.
21. XU J, LIU Y, YANG Y, BATES S, ZHANG JT: Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J. Biol. Chem. (2004) 279:19781-19789.
22. DOYLE AL, YANG W, ABRUZZO LV et al.: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA (1998) 95:15665-15670.
23. KAGE K, TSUKAHARA S, SUGIYAMA T et al.: Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer (2002)97:626-630.
24. ROSS DD: Novel mechanisms of drug resistance in leukemia. Leukemia (2000) 14:467-473.
25. KULLAK-UBLICK GA, HAGENBUCH B, STIEGER B et al.: Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology (1995) 109:1274-1282.
26. SMITH LH, LEE W, KIM RB: Differential expression of OATP drug uptake transporters in human liver, intestine, and kidney. Drug Metab. Rev. (2003) 35:73.
27. DRESSER GK, KIM RB, BAILEY DG: Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. (2005) 77:170-177. This paper represents a new mechanistic insight into drug interaction.
28. TAMAI I, NEZU J, UCHINO H et al.: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. (2000) 273:251-260.
29. ABE T, KAKYO M, TOKUI T et al.: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. (1999) 274:17159-17163.
30. HSIANG B, ZHU Y, WANG Z et al.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. (1999) 274:37161-37168.
31. KONIG J, CUI Y, NIES AT, KEPPLER D: Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. (2000) 275:23161-23168.
32. NOZAWA T, IMAI K, NEZU J, TSUJI A, TAMAI I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther. (2004) 308:438-445.
33. KULLAK-UBLICK GA, ISMAIR MG, STIEGER B et al.: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology (2001) 120:525-533.
34. SEKINE T, WATANABE N, HOSOYAMADA M, KANAI Y, ENDOU H: Expression cloning and characterization of a novel multispecific organic anion transporter. J. Biol. Chem. (1997) 272:18526-18529.
35. DRESSER MJ, LEABMAN MK, GIACOMINI KM: Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J. Pharm. Sci. (2001) 90:397-421.
36. MIYAZAKI H, SEKINE T, ENDOU H: The multispecific organic anion transporter family: properties and pharmacological significance. Trends Pharmacol. Sci. (2004) 25:654-662. This review describes the basic function of OATs in humans.
37. ENDOU H: Recent advances in molecular mechanisms of nephrotoxicity. Toxicol. Lett. (1998) 102-103:29-33.
38. CIHLAR T, LIN DC, PRITCHARD JB, FULLER MD, MENDEL DB, SWEET DH: The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter I. Mol. Pharmacol. (1999) 56:570-580.
39. HO ES, LIN DC, MENDEL DB, CIHLAR T: Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. (2000) 11:383-393.
40. JARIYAWAT S, SEKINE T, TAKEDA M et al.: The interaction and transport of β-lactam antibiotics with the cloned rat renal organic anion transporter I. J. Pharmacol. Exp. Ther. (1999) 290:672-677.
41. SIMONSON GD, VINCENT AC, ROBERG KJ, HUANG Y, IWANIJ V: Molecular cloning and characterization of a novel liver-specific transport protein. J. Cell Sci. (1994) 107:1065-1072.
42. SEKINE T, CHA SH, TSUDA M et al.: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. (1998) 429:179-182.
43. NAGATA Y, KUSUHARA H, ENDOU H, SUGIYAMA Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol. Pharmacol. (2002) 61:982-988.
44. SWEET DH, MILLER DS, PRITCHARD JB, FUJIWARA Y, BEIER DR, NIGAM SK: Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J. Biol. Chem. (2002) 277:26934-26943.
45. JONKER JW, SCHINKEL AH: Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther. (2004) 308:2-9.
46. BURCKHARDT G, WOLFF NA: Structure of renal organic anion and cation transporters. Am. J. Physiol. Renal Physiol. (2000) 278:F853-F866.
47. ZHANG L, DRESSER MJ, GRAY AT, YOST SC, TERASHITA S, GIACOMINI KM: Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. (1997) 51:913-921.
48. GORBOULEV V, ULZHEIMER JC, AKHOUNDOVA A et al.: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. (1997) 16:871-881.
49. VERHAAGH S, SCHWEIFER N, BARLOW DP, ZWART R: Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics (1999) 55:209-218.
50. SCHWAB M, EICHELBAUM M, FROMM MF: Genetic polymorphisms of the human MDR1 drug transporter. Ann. Rev. Pharmacol. Toxicol. (2003) 43:285-307. A comprehensive review of the ABCB1 polymorphism.
51. FROMM MF: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. (2002) 54:1295-1310.
52. KIM RB: Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev. (2002) 34:47-54.
53. WACHER VJ, WU CY, BENET LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. (1995) 13:129-134.
54. KIM RB, WANDEL C, LEAKE B et al.: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. (1999) 16:408-414.
55. JEDLITSCHKY G, LEIER I, BUCHHOLZ U, BARNOUIN K, KURZ G, KEPPLER D: Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. (1996) 56:988-994.
56. PRIEBE W, KRAWCZYK M, KUO MT, YAMANE Y, SAVARAJ N, ISHIKAWA T: Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem. Biophys. Res. Commun. (1998) 247:859-863.
57. BAKOS E, EVERS R, SINKO E, VARADI A, BORST P, SARKADI B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. (2000) 57:760-768.
58. ISHIKAWA T: The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci. (1992) 17:463-468.
59. LOE DW, ALMQUIST KC, DEELEY RG, COLE SP: Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. (1996) 271:9675-9682.
60. JONKER JW, SMIT JW, BRINKHUIS RF et al.: Role of breast cancer resistance protein in the bioavailabiliry and fetal penetration of topotecan. J. Natl. Cancer Inst. (2000) 92:1651-1656.
61. SUZUKI M, SUZUKI H, SUGIMOTO Y, SUGIYAMA Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem. (2003) 278:22644-22649.
62. BORST P, EVERS R, KOOL M, WIJNHOLDS J: A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. (2000) 92:1295-1302.
63. LITMAN T, BRANGI M, HUDSON E et al.: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. (2000) 113:2011-2021.
64. ECKHARDT U, SCHROEDER A, STIEGER B et al.: Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am. J. Physiol. (1999) 276:G1037-G1042.
65. CVETKOVIC M, LEAKE B, DROMM MF, WILKINSON GR, KIM RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. (1999) 27:866-871.
66. GAO B, HAGENBUCH B, KULLAK-UBLICK GA, BENKE D, AGUZZI A, MEIER PJ: Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J. Pharmacol. Exp. Ther. (2000) 294:73-79.
67. CUI Y, KONIG J, LEIER I, BUCHHOLZ U, KEPPLER D: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem. (2001) 276:9626-9630.
68. NAKAI D, NAKAGOMI R, FURUTA Y et al.: Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J. Pharmacol. Exp. Ther. (2001) 297:861-867.
69. CHUNG JY, CHO JY, YU KS et al.: Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. (2005) 78:342-350.
70. ABE T, UNNO M, ONOGAWA T et al.: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology (2001) 120:1689-1699.
71. UWAI Y, OKUDA M, TAKAMI K, HASHIMOTO Y, INUI K: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. (1998) 438:321-324.
72. APIWATTANAKUL N, SEKINE T, CHAIROUNGDUA A et al.: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol. Pharmacol. (1999) 55:847-854.
73. MORITA N, KUSUHARA H, SEKINE T, ENDOU H, SUGIYAMA Y: Functional characterization of rat organic onion transporter 2 in LLC-PK1 cells. J. Pharmacol. Exp. Ther. (2001) 298:1179-1184.
74. GOTTESMAN MM, HRYCYNA CA, SCHOENLEIN PV, GERMANN UA, PASTAN I: Genetic analysis of the multidrug transporter. Ann. Rev. Genet. (1995) 29:607-649.
75. BODOR M, KELLY EJ, HO RJ: Characterization of the human MDR1 gene. AAPS J. (2005) 7:E1-E5.
76. MICKLEY LA, LEE JS, WENG Z et al.: Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood (1998) 91:1749-1756.
77. HOFFMEYER S, BURK O, VON RICHTER O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA (2000) 97:3473-3478. This paper represents the first evidence of the functional significance of the ABCB1 gene polymorphism.
78. TANABE M, IEIRI I, NAGATA N et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. (2001) 297:1137-1143.
79. ITO S, IEIRI I, TANABE M, SUZUKI A, HIGUCHI S, OTSUBO K: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenctics (2001) 11:175-184.
80. CASCORBI I, GERLOFF T, JOHNE A et al.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. (2001) 69:169-174.
81. KIM RB, LEAKE BF, CHOO EF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. (2001) 70:189-199.
82. IEIRI I, TAKANE H, OTSUBO K: The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin. Pharmacokinet. (2004) 43:553-576. This review describes the roles of the ABCB1 polymorphism in human tissue expression, its pharmacokinetic/pharmacodynamic impact, as well as the inter-racial variability of allelic frequencies.
83. TANG K, NGOI SM, GWEE PC et al.: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics (2002) 12:437-450. Haplotype assessment of the ABCB1 gene polymorphism.
84. CHOWBAY B, CUMARASWAMY S, CHEUNG YB, ZHOU Q, LEE EJ: Genetic polymorphisms in MDR1 and CYF3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics (2003) 13:89-95.
85. KROETZ DL, PAULI-MAGNUS C, HODGES LM et al.; PHARMACOGENETICS OF MEMBRANE TRANSPORTERS INVESTIGATORS: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics (2003) 13:481-494.
86. SAI K, KANIWA N, ITODA M et al.: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics (2003) 13:741-757.
87. AMEYAW MM, REGATEIRO F, LI T et al.: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics (2001) 11:217-221.
88. LINDHOLM A, WELSH M, ALTON C, KAHAN BD: Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin. Pharmacol. Ther. (1992) 52:359-371.
89. MANCINELLI LM, FRASSETTO L, FLOREN LC et al.: The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin. Pharmacol. Ther. (2001) 69:24-31.
90. ELMORE JG, MOCERI VM, CARTER D, LARSON EB: Breast carcinoma tumor characteristics in black and white women. Cancer (1998) 83:2509-2515.
91. TSUJII H, KONIG J, ROST D, STOCKEL B, LEUSCHNER U, KEPPLER D: Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology (1999) 117:653-660.
92. TOH S, WADA M, UCHIUMI T et al.: Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. (1999) 64:739-746.
93. WADA M: Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response. Cancer Lett. (2006) 234:40-50. This review summarises ABCC2 gene variants in DJS.
94. ALLIKMETS R, SCHRIML LM, HUTCHINSON A, ROMANO-SPICA V, DEAN M: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. (1998) 58:5337-5339.
95. IIDA A, SAITO S, SEKINE A et al.: Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J. Hum. Genet. (2002) 47:285-310.
96. ZAMBER CP, LAMBA JK, YASUDA K et al.: Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics (2003) 13:19-28.
97. KOBAYASHI D, IEIRI I, HIROTA T et al.: Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. (2005) 33:94-101.
98. BACKSTROM G, TAIPALENSUU J, MELHUS H et al.: Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur. J. Pharm. Sci. (2003) 18:359-364.
99. IIDA A, SAITO S, SEKINE A et al.: Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH: ubiquinone oxidoreductase flavoproteins. J. Hum. Genet. (2001) 46:668-683.
100. LEE W, GLAESER H, SMITH LH et al.: Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. (2005) 280:9610-9617.
101. TIRONA RG, LEAKE BF, MERINO G, KIM RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. (2001) 276:35669-35675.
102. NIEMI M, SCHAEFFELER E, LANG T et al.: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 14:429-440.
103. NISHIZATO Y, IEIRI I, SUZUKI H et al.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. (2003) 73:554-565. First evidence of in vivo (human) function of the SLCO1B1 gene polymorphism.
104. MWINYI J, JOHNE A, BAUER S, ROOTS I, GERLOFF T: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. (2004) 75:415-421. Inverse effects of *5 and *1b allele on pravastatin pharmacokinetics.
105. TAKANE H, MIYATA M, BURIOKA N et al.: Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J. Hum Genet. (2006) (In Press).
106. FUJITA T, BROWN C, CARLSON EJ et al.: Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet. Genomics (2005) 15:201-209.
107. XU G, BHATNAGAR V, WEN G, HAMILTON BA, ERALY SA, NIGAM SK: Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney Int. (2005) 68:1491-1499.
108. ITODA M, SAITO Y, MAEKAWA K et al.: Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab. Pharmacokincet. (2004) 19:308-312.
109. SHU Y, LEABMAN MK, FENG B et al.; PHARMACOGENETICS OF MEMBRANE TRANSPORTERS INVESTIGATORS: Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl. Acad. Sci. USA (2003) 100:5902-5907.
110. KERB R, BRINKMANN U, CHATSKAIA N et al.: Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics (2002) 12:591-595.
111. FUKUSHIMA-UESAKA H, MAEKAWA K, OZAWA S et al.: Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab. Pharmacokinet. (2004) 19:239-244.
112. LEABMAN MK, HUANG CC, KAWAMOTO M et al.; PHARMACOGENETICS OF MEMBRANE TRANSPORTERS INVESTIGATORS: Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics (2002) 12:395-405.
113. SAITO S, UDA A, SEKINE A et al.: Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. J. Hum. Genet. (2002) 47:576-584.
114. SAKAEDA T: MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab. Pharmacokinet. (2005) 20:391-414.
115. PAULI-MAGNUS C, KROETZ DL: Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm. Res. (2004) 21:904-913. A balanced overview of the ABCB1 gene polymorphism.
116. MARZOLINI C, PAUS E, BUCLIN T, KIM RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. (2004) 75:13-33. A comprehensive review of the ABCB1 polymorphism including discussion of the possible reasons for conflicting results among studies.
117. SAKAEDA T, NAKAMURA T, HORINOUCHI M et al.: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. (2001) 18:1400-1404.
118. KURATA Y, IEIRI I, KIMURA M et al.: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. (2002) 72:209-219.
119. JOHNE A, KOPKE K, GERLOFF T et al.: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. (2002) 72:584-594.
120. WANG D, JOHNSON AD, PAPP AC, KROETZ DL, SADEE W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet. Genomics (2005) 15:693-704.
121. HIROTA T, IEIRI I, TAKANE H et al.: Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Hum. Mol. Genet. (2004) 13:2959-2969.
122. WOJNOWSKI L, BROCKMOLLER J: Single nucleotide polymorphism characterization by mRNA expression imbalance assessment. Pharmacogenetics (2004) 14:267-269.
123. BRUNNER M, LANGER O, SUNDER-PLASSMANN R et al.: Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin. Pharmacol. Ther. (2005) 78:182-190.
124. HENDRIKSE NH, DE VRIES EG, ERIKS-FLUKS L et al.: A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res. (1999) 59:2411-2416.
125. SPARREBOOM A, GELDERBLOM H, MARSH S et al.: Diflomotecan pharmacokinetics in relation to ABCG2 421C > A genotype. Clin. Pharmacol. Ther. (2004) 76:38-44. First evidence of in vivo (human) function of the ABCG2 gene polymorphism.
126. IMAI Y, NAKANE M, KAGE K et al.: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. (2002) 1:611-616.
127. KONDO C, SUZUKI H, ITODA M et al.: Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. (2004) 21:1895-1903.
128. SPARREBOOM A, LOOS WJ, BURGER H et al.: Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol. Ther. (2005) 4:650-658.
129. DE JONG FA, MARSH S, MATHIJSSEN RH et al.: ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. (2004) 10:5889-5894.
130. OLOMBO S, SORANZO N, ROTGER M et al.: Influence of ABCB1, ABCC1, ABCC2, and ABCG2 heplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet. Genomics (2005) 15:599-608.
131. SEKINO H, ONOSHI T, SEKINO H: Phase I study of ZD-4522 (rosuvastatin), a new HMG-CoA reductase inhibitor-evaluation of tolerance and pharmacokinetics in healthy adult male volunteers after single and repeated oral administration. J. Clin. Ther. Med. (2005) 21:187-203.
132. WARWICK MJ, DANE AL, RAZA A, ACHNECK DW: Single and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD-4522 [abstract]. Atherosclerosis (2000) 151:39.
133. MARTIN PD, MITCHELL PD, SCHNECK DW: Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br. J. Clin. Pharmacol. (2002) 54:472-477.
134. SIMONSON SG, RAZA A, MARTIN PD et al.: Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. (2004) 76:167-177.
135. LEE E, RYAN S, BIRMINGHAM B et al.: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. (2005) 78:330-341.
136. TIRONA RG: Ethnic differences in statin disposition. Clin. Pharmacol. Ther. (2005) 78:311-316.
137. NIEMI M, KIVISTO KT, HOFMANN U, SCHWAB M, EICHELBAUM M, FROMM MF: Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br. J. Clin. Pharmacol. (2005) 59:602-604.
138. NIEMI M, BACKMAN JT, KAJOSAARI LI et al.: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. (2005) 77:468-478.
139. MAEDA K, IEIRI I, YASUDA K et al.: Effects of OATP1B1 haplotype on pharmacokinetics of pravastatin, valsartan and temocapril. Clin. Pharmacol. Ther. (2006) 79:427-439.
140. KAMEYAMA Y, YAMASHITA K, KOBAYASHI K, HOSOKAWA M, CHIBA K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics (2005) 15:513-522.
141. IWAI M, SUZUKI H, IEIRI I, OTSUBO K, SUGIYAMA Y: Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenet. Genomics (2004) 14:749-757.
142. LEABMAN M, BROWN C, CHUNG J et al.: Heritability of metformin renal clearance. Clin. Pharmacol. Ther. (2005) 77:P61.
143. FELLAY J, MARZOLINI C, MEADEN ER et al.: Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 359:30-36.
144. HAAS DW, SMEATON LM, SHAFER RW et al.: Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study. J. Infect. Dis. (2005) 192:1931-1942.
145. NASI M, BORGHI V, PINTI M et al.: MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS (2003) 17:1696-1698.
146. WINZER R, LANGMANN P, ZILLY M et al.: No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naive HIV-positive patients. Ann. Clin. Microbiol. Antimicrob. (2005) 4:1-7.
147. LOSCHER W, POTSCHKA H: Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther. (2002) 301:7-14.
148. TISHLER DM, WEINBERG KI, HINTON DR, BARBARO N, ANNETT GM, RAFFEL C: MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia (1995) 36:1-6.
149. SISODIYA SM, LIN WR, SQUIER MV, THOM M: Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet (2001) 357:42-43.
150. SISODIYA SM, LIN WR, HARDING BN, SQUIER MV, THOM M: Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain (2002) 125:22-31.
151. DOMBROWSKI SM, DESAI SY, MARRONI M et al.: Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia (2001) 42:1501-1506.
152. SIDDIQUI A, KERB R, WEALE MR et al.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. (2003) 348:1442-1448.
153. TAN NC, HERON SE, SCHEFFER IE et al.: Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology (2004) 63:1090-1092.
154. SILLS GJ, MOHANRAJ R, BUTLER E et al.: Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia (2005) 46:643-647.
155. ILLMER T, SCHULER US, THIEDW C et al.: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. (2002) 62:4955-4962.
156. VAN DEN HEUVEL-EIBRINK MM, WIEMER EA, DE BOEVERE MJ et al.: MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood (2001) 97:3605-3611.
157. EFFERTH T, SAUERBREY A, STEINBACH D et al.: Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int. J. Oncol. (2003) 23:509-517.
158. GOREVA OB, GRISHANOVA AY, MUKHIN OV, DOMNIKOVA NP, LYAKHOVICH VV: Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms. Bull. Exp. Biol. Med. (2003) 136:183-185.
159. ISLA D, SARRIES C, ROSELL R et al.: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. (2004) 15:1194-1203.
160. PLASSCHAERT SL, GRONINGER E, BOEZEN M et al.: Influence of
161. YAMAUCHI A, IEIRI I, KATAOKA Y et al.: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation (2002) 74:571-572.
162. HAUSER IA, SCHAEFFELER E, GAUER S et al.: ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol. (2005) 16:1501-1511.
163. DROZDZIK M, MYSLIWIEC K, LEWINSKA-CHELSTOWSKA M, DANACH J, DROZDZIK A, GRABAREK J: P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. J. Clin. Periodontol. (2004) 31:758-763.
164. FURUNO T, LANDI MT, CERONI M et al.: Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics (2002) 12:529-534.
165. DROZDZIK M, BIALECKA M, MYSLIWIEC K, HONCZARENKO K, STANKIEWICZ J, SYCH Z: Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics (2003) 13:259-263.
166. TAN EK, DROZDZIK M, BIALECKA M et al.: Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neurosci. Lett. (2004) 372:240-244.
167. TAN EK, CHAN DK, NG PW et al.: Effect of MDR1 haplotype on risk of Parkinson's disease. Arch. Neurol. (2005) 62:460-464.
168. SCHWAB M, SCHAEFFELER E, MARX C et al.: Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology (2003) 124:26-33.
169. CROUCHER PJ, MASCHERETTI S, FOELSCH UR, HAMPE J, SCHREIBER S: Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent Northern European populations. Gastroenterotogy (2003) 125:1919-1920.
170. BRANT SR, PANHUYSEN CI, NICOLAE D et al.: MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am. J. Hum. Genet. (2003) 73:1282-1292.
171. GAZOULI M, ZACHARATOS P, GORGOULIS V, MANTZARIS G, PAPALAMBROS E, IKONOMOPOULOS J: The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population. Gastroenterology (2004) 126:367-369.
172. GLAS J, TOROK HP, SCHIEMANN U, FOLWACZNY C: MDR1 gene polymorphism in ulcerative colitis. Gastroenterology (2004) 126:367.
173. POTOCNIK U, FERKOLJ I, GLAVAC D, DEAN M: Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. (2004) 5:530-539.
174. HOGT, NIMMO ER, TENESA A et al.: Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerativc colitis. Gastroenterology (2005) 128:288-296.
175. URCELAY E, MENDOZA JL, MARTIN MC et al.: MDR1 gene: susceptibility in Spanish Crohn's disease and ulcerative colitis patients. Inflamm. Bowel Dis. (2006) 12:33-37.
176. JAMROZIAK K, MLYNARSKI W, BALCERCZAK E et al.: Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol. (2004) 72:314-321.
177. STANULLA M, SCHAFFELER E, ARENS S et al.: GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int. J. Hematol. (2005) 81:39-44.
178. POTOCNIK U, RAVNIK-GLAVAC M, GOLOUH R, GLAVAC D: Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers. J. Med. Genet. (2002) 39:340-346.
179. KURZAWSKI M, DROZDZIK M, SUCHY J et al.: Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur. J. Clin. Pharmacol. (2005) 61:389-394.
180. HUMENY A, RODEL F, RODEL C et al.: MDR1 single nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinomas detected by MALDI-TOF mass spectrometry. Anti-Cancer Res. (2003) 23:2735-2740.
181. SIEGSMUND M, BRINKMANN U, SCHAFFELER E et al.: Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. (2002) 13:1847-1854.
182. MILLER KL, KELSEY KT, WIENCKE JK et al.: The C3435T polymorphism of MDR1 and susceptibility to adult glioma. Neuroepidemiology (2005) 25:85-90.
183. KIMURA Y, SELMI C, LEUNG PS et al.: Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. Hepatology (2005) 41:55-63.
184. PAWLIK A, WRZESNIEWSKA J, FIEDOROWICZ-FABRYCY I, GAWRONSKA-SZKLARZ B: The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. (2004) 42:496-503.
185. KIVISTO KT, NIEMI M, SCHAEFFELER E et al.: CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study. Am. J. Pharmacogenomics (2005) 5:191-195.
186. LENNERNAS H, FAGER G: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. (1997) 32:403-425.
187. TOBERT JA: Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. (2003) 2:517-526.
188. TACHIBANA-IIMORI R, TABARA Y, KUSUHARA H et al.: Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. (2004) 19:375-380.
189. NIEMI M, NEUVONEN PJ, HOFMANN U et al.: Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics (2005) 15:303-309. Pharmacodynamic consequence of SLCO1B1 variants on cholesterol synthesis in humans.
190. HIRANO M, MAEDA M, MATSUSHIMA S, NOZAKI Y, KUSUHARA H, SUGIYAMA Y: Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. (2005) 68:800-807.
191. VERSTUYFT C, SCHWAB M, SCHAEFFELER E et al.: Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol. (2003) 58:809-812.
192. GERLOFF T, SCHAEFER M, JOHNE A et al.: MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol. (2002) 54:610-616.
193. YI SY, HONG KS, LIM HS et al.: A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin. Pharmacol. Ther. (2004) 76:418-427.
194. DRESCHER S, SCHAEFFELER E, HITZL M et al.: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. (2002) 53:526-534.
195. VON AHSEN N, RICHTER M, GRUPP C, RINGE B, OELLERICH M, ARMSTRONG VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. (2001) 47:1048-1052.
196. MIN DI, ELLINGROD VL: C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. (2002) 24:400-404.
197. YATES CR, ZHANG W, SONG P et al.: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. (2003) 43:555-564.
198. BONHOMME-FAIVRE L, DEVOCELLE A, SALIBA F et al.: MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation (2004) 78:21-25.
199. MACPHEE IA, FREDERICKS S, TAI T et al.: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation (2002) 74:1486-1489.
200. ZHENG H, WEBBER S, ZEEVI A et al.: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. (2003) 3:477-483.
201. HAUFROID V, MOURAD M, VAN KERCKHOVE V et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics (2004) 14:147-154.
202. SIEGMUND W, LUDWIG K, GIESSMANN T et al.: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. (2002) 72:572-583.
203. ZHANG WX, CHEN GL, ZHANG W et al.: MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males. Clin. Chim. Acta. (2005) 359:46-52.
204. RODRIGUEZ NOVOA S, BARREIRO P, RENDON A et al.: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis. (2006) 42:291-295.
205. PAULI-MAGNUS C, FEINER J, BRETT C et al.: No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin. Pharmacol. Ther. (2003) 74:487-498.
206. PUTNAM WS, WOO JM, HUANG Y, BENET LZ: Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. J. Clin. Pharmacol. (2005) 45:411-421.
207. KERB R, AYNACIOGLU AS, BROCKMOLLER J et al.: The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. (2001) 1:204-210. This paper offers a new approach, the gene-network trial (multiple gene analysis), for the prediction of individual phenytoin disposition.
208. YASUI-FURUKORI N, MIHARA K, TAKAHATA T et al.: Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br. J. Clin. Pharmacol. (2004) 57:569-575.
209. HORINOUCHI M, SAKAEDA T, NAKAMURA T et al.: Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm. Res. (2002) 19:1581-1585.
210. ANGLICHEAU D, VERSTUYFT C, LAURENT-PUIG P et al.: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. (2003) 14:1889-1896.
211. ROBERTS RL, JOYCE PR, MULDER RT, BEGG EJ, KENNEDY MA: A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. (2002) 2:191-196.
212. BRUMME ZL, DONG WW, CHAN KJ et al.: Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS (2003) 17:201-208.
213. ALONSO-VILLAVERDE C, COLL B, GOMEZ F et al.: The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. AIDS (2005) 19:341-342.
214. ZHENG H, WEBBER S, ZEEVI A et al.: The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum. Immunol. (2002) 63:765-770.
215. KOTRYCH K, DOMANSKI L, GORNIK W, DROZDZIK M: MDR1 gene polymorphism in allogeenic kidney transplant patients with tremor. Pharmacol. Rep. (2005) 57:241-245.
216. ZHENG HX, ZEEVI A, MCCURRY K et al.: The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl. Immunol. (2005) 14:37-42.
217. KAFKA A, SAUER G, JAEGER C et al.: Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol. (2003) 22:1117-1121.
218. BABAOGLU MO, BAVAR B, AYNACIOGLU AS et al.: Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin. Pharmacol. Ther. (2005) 78:619-626.
219. YASUI-FURUKORI N, SAITO M, NAKAGAMI T, KANEDA A, TATEISHI T, KANEKO S: Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) 30(2):286-291.
220. MORIMOTO K, UEDA S, SEKI N et al.: Candidate gene approach for the study of genetic factors involved in HMG-CoA reductase inhibitor-induced rhabdomyolysis. 18th JSSX annual meeting. Sapporo, Japan. 8PE-32 (2003).